issuance of 619,700 new shares through a third-party allotment at 4,841 yen per share to raise approximately 3,000 million yen. The funds will be allocated to R&D for next-generation cardiac cell sheets, catheter therapies, internal regeneration factor inducers, and MSC development, as well as preparation and execution of future clinical trials. Allottee is JICVGI Opportunity Fund No. 1 Investment Business Type Limited Liability Partnership, dilution about 7.5%, payment deadline September 28, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4894","jir_company_name":"Qualips Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4894-20260911-01.pdf","jir_short_summary":"issuance of 619,700 new shares through a third-party allotment at 4,841 yen per share to raise approximately 3,000 million yen. The funds will be allocated to R&D for next-generation cardiac cell sheets, catheter therapies, internal regeneration factor inducers, and MSC development, as well as preparation and execution of future clinical trials. Allottee is JICVGI Opportunity Fund No. 1 Investment Business Type Limited Liability Partnership, dilution about 7.5%, payment deadline September 28, 2026.","jir_summary":"### Overview of the offering and funding purpose\nQualips will issue 619,700 new shares through a third-party allotment, raising approximately 300 million yen. The paid-in price is 4,841 yen per share, and the funds will be invested in R&D expenditure including rehart (R Heart) and clinical trial preparation costs, as well as outsourcing costs, to support growth drivers. The allottees are JICVGI Opportunity Fund No. 1 Investment Business Type LLC, with estimated dilution of about 7.5%.\n\n### Outlook and significance of capital policy\nThe fundraising will support continued growth of ReHeart domestic sales and accelerate pipeline development, including U.S. expansion of next-generation cardiac cell sheets, catheter therapies, internal regeneration factor inducers, and MSCs. The plan is to allocate funds mainly to costs for clinical trial preparation and execution, with a view to medium- to long-term increases in corporate value.","jir_financial_highlights":"Number of new shares issued: 619,700 shares (Unknown)\nPaid-in amount: 4,841 yen (Unknown)\nTotal funds raised: 2,999,967,700 yen (Unknown)\nDilution: 7.49% (shares outstanding) (Unknown)","jir_category":"","jir_hashtags":"#Qualips, #capital_policy, #third_party_allotment, #growth_investment","jir_key_figures":"New shares: 619,700 shares\nPaid-in amount: 4,841 yen\nTotal funding: 2,999,967,700 yen","jir_meta_title":"\u3010Qualips\u3011 Announcement of issuance of new shares through third-party allotment\uff5cSeptember 2026","jir_meta_description":"Qualips issues 619,700 shares at 4,841 yen through a third-party allotment to raise approximately 3,000 million yen. Funds allocated mainly to R&D and clinical trial preparation, including ReHeart-related projects. Allottee is JICVGI, dilution about 7.5%, payment deadline September 28.","jir_og_title":"\u3010Qualips\u3011 Announcement of issuance of new shares through third-party allotment\uff5cSeptember 2026","jir_og_description":"Qualips raises approximately 3,000 million yen through a new share issuance. Funds to be invested in next-generation medical development; allottee is JICVGI; dilution about 7.5%","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17194,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-113186","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n